Source Biosciences buys Cambridge Clinical Laboratories to expand clinical offering

Source BioScience has acquired Cambridge Clinical Laboratories (CCL), framing the move as a part of an effort to build its trials and diagnostics businesses.

The deal will add capabilities in clinical and personalized healthcare testing and a recently built clinical laboratory at the Vision Park campus in Cambridge, UK. Financial details were not disclosed.

According to Source BioScience, the acquisition will expand its clinical offering, which includes molecular diagnostics, digital pathology, and trial support.

A Source BioScience spokesperson told Clinical Insider, “Combining the CCL portfolio with the Source BioScience portfolio will allow the combined offering to be of even more interest for clinical trial sponsors and CROs alike.

“The enhanced portfolio allows interested parties access to cutting edge diagnostics tests, supporting both clinical trials as well as, for example, molecular profiling prior to clinical trials, minimizing risk for subsequent stages, and lowering data bias by using a single supplier for laboratory testing.”

In a press release, CCL CEO Tony Cooke said, “We welcome the opportunity to join forces with Source, which will allow us to bring together the talent and expertise of both companies, ultimately adding more capacity for customers to access these cutting-edge research services, and bring new therapies to patients, faster.”

CCL provides personalized healthcare diagnostic services spanning oncology, virology, men’s health, gastro, and fertility, as well as validation studies.

The firm’s customer base includes both the UK National Health Service and private drug industry customers.

In the trials space, CCL works directly with sponsors, providing central laboratory services and development and support services for assays.

The CCL deal is Source BioScience’s first acquisition since it bought London-based “digital pathology” testing services firm LDPath in 2022.

It also follows just over a year after Source BioScience decided to sell its stability storage unit to UK private equity firm Limerston Capital and focus further investment in its core laboratory services business.

DepositPhotos/thaneeh.gmail.com